This study shows US-guided microwave ablation appears to be a promising method to treat renal cell carcinoma adjacent to renal sinus.
The estimated 1-, 3- and 5-year RCC-related survival were 100%, 93.3% and 93.3%, respectively.
The estimated 1-, 3- and 5-year overall survival were 97.1%, 87.8%, 83.6%, respectively.
For patients with RCC ≤4 cm, initial ablation success was 100% (29/29) and the estimated 5-year disease-free survival were 81.5%.